JS Link
Financials
Valuation Metrics
JS Link's Market Cap is ₩6900B. At end of 2025 it was ₩6680B. Ranked #355 of 2,405 in KR market (top 15%), #112 of 1,627 on KOSDAQ (top 7%), #36 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 690.04B KRW | KR#355/2,405 Sec#36/231 |
| Revenue | 22.78B KRW | KR#2,104/2,405 Sec#153/231 |
| Net Income | -5.30B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 187.70B KRW | KR#1,357/2,405 Sec#99/231 |
| Net Assets | 103.50B KRW | KR#1,389/2,405 Sec#109/231 |
| Employees | 80 | KR#1,805/2,405 Sec#152/231 |
| Value | ||
| P/B | 6.67x | KR#2,307/2,405 Sec#201/231 |
| P/S | 30.32x | KR#2,346/2,405 Sec#192/231 |
| FCF Yield | -7.74% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -5.12% | KR#1,799/2,405 Sec#130/231 |
| ROA | -2.82% | KR#1,815/2,405 Sec#128/231 |
| Op. Margin | -63.17% | KR#2,240/2,405 Sec#162/231 |
| Revenue Growth | 51.26% | KR#201/2,405 Sec#27/231 |
| Financial Health | ||
| Debt Ratio | 81.35% | KR#1,359/2,405 Sec#159/231 |
| Total Debt | 54.14B KRW | KR#975/2,405 Sec#66/231 |
| FCF | -53.44B KRW | KR#2,079/2,405 Sec#206/231 |
| Cash | 72.23B KRW | KR#592/2,405 Sec#31/231 |
| Current Ratio | 1.55x | KR#1,154/2,405 Sec#127/231 |
| Performance | ||
| 1Y Return | -11.89% | KR#875/2,405 Sec#52/231 |
| 1M Return | -36.78% | KR#2,328/2,405 Sec#228/231 |
| From 52W High | -63.01% | KR#1,801/2,405 Sec#151/231 |
| 1Y MDD | -65.11% | KR#1,723/2,405 Sec#147/231 |
| Trading | ||
| Volume | 58,758 shares | KR#865/2,405 Sec#97/231 |
| Trading Value | 1.07B KRW | KR#573/2,405 Sec#60/231 |
| Foreign Own. | 3.41% | KR#1,171/2,405 Sec#107/231 |
| Per Share | ||
| EPS | -142 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,766 KRW | KR#1,919/2,405 Sec#148/231 |
Company Info
Established in 2000 as a personalized medicine specialized healthcare company, the company will change its name to JS Link in 2025. It operates genome analysis technology-based services and molecular diagnostics businesses. Through an amendment to its articles of incorporation, JS Link is expanding into the production of permanent sintered magnets for future industries like electric vehicles and robots. The company is preparing for manufacturing by securing rare earth procurement partnerships, talent, and facility investments, while pursuing innovation in its technology platform. JS Link is headquartered in Gangseo-gu, Seoul Metropolitan City.